Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The board meeting held on 30 May 2026 approved several items: (1) Audited standalone and consolidated financial results for FY ended 31 March 2026 — standalone profit after tax Rs. 2,871.03L, consolidated PAT Rs. 4,481.63L, with an unmodified audit opinion from ABMS & Associates; (2) Recommended a final dividend of Rs. 0.25 per share (2.5% on Rs. 10 face value), subject to shareholder approval at the ensuing AGM; (3) Approved raising up to Rs. 13.09 crore via issuance of 11 lakh convertible warrants at Rs. 119 each to 9 non-promoter allottees, convertible within 18 months; (4) Sought shareholder approval to raise overall borrowing limit to Rs. 700 crore under Section 180(1)(c) and (a) of the Companies Act; (5) Appointed M/s Aman Jindal & Co. as Internal Auditor and M/s Dhananjay V. Joshi & Associates as Cost Auditor for FY 2026-27; (6) Acquired a 10% stake in Virtuoso Infra Meditech LLP for Rs. 1.5 lakh via capital contribution; (7) Scheduled an Extra-Ordinary General Meeting on 29 June 2026 for shareholder approvals.
The company reported healthy full-year profitability on a consolidated basis. The Rs. 13.09 crore convertible warrants issuance will dilute equity but brings fresh capital. The proposed borrowing limit hike to Rs. 700 crore signals potential large-scale debt-funded growth or refinancing activity. The dividend and positive audit opinion are broadly positive for investor sentiment.